DOCSLIB.ORG

Statistical Analysis Plan, Final Version 1.0 ALX0061-C204 Date Issued: 28FEB2018

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Statistical Analysis Plan, Final Version 1.0 ALX0061-C204 Date Issued: 28FEB2018 Ablynx Statistical Analysis Plan, Final Version 1.0 ALX0061-C204 Date Issued: 28FEB2018 Ablynx ALX0061-C204 A Phase II Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-range Finding Study to Evaluate the Safety and Efficacy of ALX-0061 Administered Subcutaneously in Subjects with Moderate to Severe Active Systemic Lupus Erythematosus 28FEB2018 Statistical Analysis Plan Final Version 1.0 1 Page 2 of 135 Ablynx Statistical Analysis Plan, Final Version 1.0 ALX0061-C204 Date Issued: 28FEB2018 TABLE OF CONTENTS LIST OF ABBREVIATIONS .................................................................................... 6 1 INTRODUCTION......................................................................................... 9 2 OBJECTIVES ............................................................................................ 10 2.1 PRIMARY OBJECTIVE ......................................................................................... 10 2.2 SECONDARY OBJECTIVES ................................................................................... 10 3 INVESTIGATIONAL PLAN......................................................................... 10 3.1 OVERALL STUDY DESIGN AND PLAN ...................................................................... 10 3.1.1 Sample Size ....................................................................................... 11 3.1.2 Blinding and Unblinding ....................................................................... 12 3.1.2.1 Study Drug Administration Blinding ................................................. 12 3.1.2.2 Blinding of Potentially Unblinding Parameters ................................... 12 3.1.2.3 Emergency Unblinding ................................................................... 12 3.2 STUDY ENDPOINTS .......................................................................................... 13 3.2.1 Primary Endpoint ................................................................................ 13 3.2.2 Secondary Endpoints ........................................................................... 13 4 GENERAL STATISTICAL CONSIDERATIONS.............................................. 16 4.1 ANALYSIS POPULATIONS .................................................................................... 19 4.1.1 All Screened Population ....................................................................... 19 4.1.2 All Randomized Population ................................................................... 19 4.1.3 Modified Intent-to-Treat (mITT) Population ............................................ 19 4.1.4 Per Protocol (PP) Population ................................................................. 19 4.1.5 Safety Population ................................................................................ 23 5 SUBJECT DISPOSITION ........................................................................... 23 5.1 DISPOSITION ................................................................................................. 23 5.2 ANALYSIS POPULATIONS .................................................................................... 24 5.3 PROTOCOL DEVIATIONS .................................................................................... 24 6 DEMOGRAPHICS AND BASELINE CHARACTERISTICS ............................... 24 6.1 DEMOGRAPHICS ............................................................................................. 24 6.2 BASELINE DISEASE CHARACTERISTICS ................................................................... 25 6.3 TOBACCO USAGE ............................................................................................ 26 6.4 MEDICAL HISTORY .......................................................................................... 26 6.5 ADDITIONAL SCREENING/BASELINE ASSESSMENTS .................................................... 26 7 TREATMENTS AND MEDICATIONS ........................................................... 26 7.1 PRIOR AND CONCOMITANT MEDICATIONS ................................................................ 26 7.1.1 Prior Medications ................................................................................ 27 7.1.2 Concomitant Medications ..................................................................... 27 7.2 STUDY TREATMENTS ........................................................................................ 27 8 EFFICACY ANALYSIS ............................................................................... 28 8.1 PRIMARY EFFICACY ENDPOINT ............................................................................. 29 8.1.1 Primary Analysis ................................................................................. 30 8.1.2 Assumption Testing ............................................................................. 34 8.1.3 Sensitivity Analysis ............................................................................. 34 8.1.4 Subgroup Analysis .............................................................................. 34 8.2 SECONDARY EFFICACY ENDPOINTS........................................................................ 35 8.2.1 mBICLA ............................................................................................. 35 8.2.2 BICLA ................................................................................................ 35 8.2.3 SRI ................................................................................................... 36 2 Page 3 of 135 Ablynx Statistical Analysis Plan, Final Version 1.0 ALX0061-C204 Date Issued: 28FEB2018 8.2.4 mSRI ................................................................................................ 36 8.2.5 SLEDAI-2K ......................................................................................... 37 8.2.6 mSLEDAI-2K ...................................................................................... 37 8.2.7 BILAG-2004 Improvement ................................................................... 37 8.2.8 BILAG-2004 Total Score ...................................................................... 38 8.2.9 BILAG-2004 Improvement by Individual Organ System ........................... 38 8.2.10 BILAG-2004 Systems Tally ................................................................... 38 8.2.11 PGA .................................................................................................. 39 8.2.12 Patient’s Global Assessment ................................................................. 39 8.2.13 Laboratory Efficacy Assessment ............................................................ 39 8.2.14 Treatment Failure ............................................................................... 40 8.2.15 BILAG-2004 Flare ............................................................................... 40 8.2.16 mSLEDAI-2K Flare (mSFI) ................................................................... 40 8.2.17 Prednisone Equivalent Total Daily Dose ................................................. 40 8.2.18 Reduction Rate in Steroids Intake Without Severe Flare ........................... 41 8.2.19 Discontinuation Rate in Steroids Intake without Severe Flare ................... 41 8.2.20 SF-36 Physical and Mental Component .................................................. 41 8.2.21 28-Joint Count.................................................................................... 42 8.2.22 CLASI ................................................................................................ 42 9 SAFETY ANALYSIS ................................................................................... 42 9.1 ADVERSE EVENTS ........................................................................................... 42 9.1.1 Incidence of Adverse Events................................................................. 43 9.1.2 Relationship of Adverse Events to Study Drug ........................................ 44 9.1.3 Severity of Adverse Event .................................................................... 44 9.1.4 Serious Adverse Events ....................................................................... 44 9.1.5 Adverse Events Leading to Treatment Discontinuation ............................. 44 9.1.6 Adverse Event of Special Interest (AESI) ............................................... 44 9.1.7 Death ................................................................................................ 45 9.2 CLINICAL LABORATORY EVALUATIONS .................................................................... 46 9.2.1 Haematology, Blood Chemistry, Lipid Profile and Coagulation ................... 46 9.2.2 Urinalysis ........................................................................................... 47 9.2.3 Laboratory Parameters of Special Interest ............................................. 47 9.2.4 Coombs’ test ...................................................................................... 47 9.2.5 INR ................................................................................................... 47 9.2.6 Antibodies .......................................................................................... 48 9.3 VITAL SIGN MEASUREMENTS .............................................................................. 48 9.4 PHYSICAL EXAMINATION .................................................................................... 49 9.5 ELECTROCARDIOGRAM ...................................................................................... 49 9.6 OTHER SAFETY DATA ......................................................................................
Load more

Recommended publications
  • Distribution of Tick-Borne Diseases in China Xian-Bo Wu1, Ren-Hua Na2, Shan-Shan Wei2, Jin-Song Zhu3 and Hong-Juan Peng2*
    Wu et al. Parasites & Vectors 2013, 6:119 http://www.parasitesandvectors.com/content/6/1/119 REVIEW Open Access Distribution of tick-borne diseases in China Xian-Bo Wu1, Ren-Hua Na2, Shan-Shan Wei2, Jin-Song Zhu3 and Hong-Juan Peng2* Abstract As an important contributor to vector-borne diseases in China, in recent years, tick-borne diseases have attracted much attention because of their increasing incidence and consequent significant harm to livestock and human health. The most commonly observed human tick-borne diseases in China include Lyme borreliosis (known as Lyme disease in China), tick-borne encephalitis (known as Forest encephalitis in China), Crimean-Congo hemorrhagic fever (known as Xinjiang hemorrhagic fever in China), Q-fever, tularemia and North-Asia tick-borne spotted fever. In recent years, some emerging tick-borne diseases, such as human monocytic ehrlichiosis, human granulocytic anaplasmosis, and a novel bunyavirus infection, have been reported frequently in China. Other tick-borne diseases that are not as frequently reported in China include Colorado fever, oriental spotted fever and piroplasmosis. Detailed information regarding the history, characteristics, and current epidemic status of these human tick-borne diseases in China will be reviewed in this paper. It is clear that greater efforts in government management and research are required for the prevention, control, diagnosis, and treatment of tick-borne diseases, as well as for the control of ticks, in order to decrease the tick-borne disease burden in China. Keywords: Ticks, Tick-borne diseases, Epidemic, China Review (Table 1) [2,4]. Continuous reports of emerging tick-borne Ticks can carry and transmit viruses, bacteria, rickettsia, disease cases in Shandong, Henan, Hebei, Anhui, and spirochetes, protozoans, Chlamydia, Mycoplasma,Bartonia other provinces demonstrate the rise of these diseases bodies, and nematodes [1,2].
    [Show full text]
  • Vectorborne Zoonoses: Break-Out Session Epidemiology and Laboratory Capacity Workshop – Oct
    Texas Department of State Health Services Vectorborne Zoonoses: Break-out Session Epidemiology and Laboratory Capacity Workshop – Oct. 2018 DSHS Zoonosis Control Branch Session Topics Texas Department of State Health Services • NEDSS case investigation tips • Lyme disease • Rickettsial diseases • Arboviral diseases ELC 2018 - Vectorborne Diseases 2 Texas Department of State Health Services Don’t be a Reject! Helpful tips to keep your notification from being rejected ELC breakout session October 3, 2018 Kamesha Owens, MPH Zoonosis Control Branch Texas Department of State Health Services Objectives • Rejection Criteria • How to document in NBS (NEDSS) • How to Report Texas Department of State Health Services 10/3/2018 ELC 2018 - Vectorborne Diseases 4 Rejection Criteria Texas Department of State Health Services Missing/incorrect information: • Incorrect case status or condition selected • Full Name • Date of Birth • Address • County • Missing laboratory data 10/3/2018 ELC 2018 - Vectorborne Diseases 5 Rejection Criteria continued Texas Department of State Health Services • Inconsistent information • e.g. Report date is a week before onset date • Case investigation form not received by ZCB within 14 days of notification • ZCB recommends that notification not be created until the case is closed and the investigation form has been submitted 10/3/2018 ELC 2018 - Vectorborne Diseases 6 Rejection Criteria continued Texas Department of State Health Services • Condition-specific information necessary to report the case is missing: • Travel history for Zika and other non-endemic conditions • Evidence of neurological disease for WNND case • Supporting documentation for Lyme disease case determination 10/3/2018 ELC 2018 - Vectorborne Diseases 7 How to Document in NBS (NEDSS) Do Don’t Add detailed comments in designated Leave us guessing! comments box under case info tab.
    [Show full text]
  • Glossary for Narrative Writing
    Periodontal Assessment and Treatment Planning Gingival description Color: o pink o erythematous o cyanotic o racial pigmentation o metallic pigmentation o uniformity Contour: o recession o clefts o enlarged papillae o cratered papillae o blunted papillae o highly rolled o bulbous o knife-edged o scalloped o stippled Consistency: o firm o edematous o hyperplastic o fibrotic Band of gingiva: o amount o quality o location o treatability Bleeding tendency: o sulcus base, lining o gingival margins Suppuration Sinus tract formation Pocket depths Pseudopockets Frena Pain Other pathology Dental Description Defective restorations: o overhangs o open contacts o poor contours Fractured cusps 1 ww.links2success.biz [email protected] 914-303-6464 Caries Deposits: o Type . plaque . calculus . stain . matera alba o Location . supragingival . subgingival o Severity . mild . moderate . severe Wear facets Percussion sensitivity Tooth vitality Attrition, erosion, abrasion Occlusal plane level Occlusion findings Furcations Mobility Fremitus Radiographic findings Film dates Crown:root ratio Amount of bone loss o horizontal; vertical o localized; generalized Root length and shape Overhangs Bulbous crowns Fenestrations Dehiscences Tooth resorption Retained root tips Impacted teeth Root proximities Tilted teeth Radiolucencies/opacities Etiologic factors Local: o plaque o calculus o overhangs 2 ww.links2success.biz [email protected] 914-303-6464 o orthodontic apparatus o open margins o open contacts o improper
    [Show full text]
  • Dry Socket (Alveolar Osteitis): Incidence, Pathogenesis, Prevention and Management
    See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/273250883 Dry Socket (Alveolar Osteitis): Incidence, Pathogenesis, Prevention and Management Article · January 2013 CITATIONS READS 4 6,266 4 authors, including: Deepak Viswanath Mahesh kumar R krishnadevaraya college of dental sciences krishnadevaraya college of dental sciences 46 PUBLICATIONS 131 CITATIONS 14 PUBLICATIONS 29 CITATIONS SEE PROFILE SEE PROFILE Some of the authors of this publication are also working on these related projects: AID reviews View project Systematic Reviews View project All content following this page was uploaded by Mahesh kumar R on 08 March 2015. The user has requested enhancement of the downloaded file. GirishREVIEW G Gowda ARTICLE et al Dry Socket (Alveolar Osteitis): Incidence, Pathogenesis, Prevention and Management Girish G Gowda, Deepak Viswanath, Mahesh Kumar, DN Umashankar ABSTRACT registered.12-15 The duration varies from 5 to 10 days Alveolar osteitis (AO) is the most common postoperative depending on the severity of the condition. complication after tooth extraction. The pathophysiology, etiology, prevention and treatment of the alveolar osteitis are ETIOLOGY very essential in oral surgery. The aim of this article is to provide a better basis for clinical management of the condition. In The exact etiology of AO is not well understood. Birn addition, the need for identification and elimination of the risk suggested that the etiology of AO is an increased local factors as well as preventive and symptomatic management of fibrinolysis leading to disintegration of the clot. However, the condition are discussed. several local and systemic factors are known to be Keywords: Alveolar osteitis, Localised osteitis, Septic socket, contributing to the etiology of AO.
    [Show full text]
  • Zeroing in on the Cause of Your Patient's Facial Pain
    Feras Ghazal, DDS; Mohammed Ahmad, Zeroing in on the cause MD; Hussein Elrawy, DDS; Tamer Said, MD Department of Oral Health of your patient's facial pain (Drs. Ghazal and Elrawy) and Department of Family Medicine/Geriatrics (Drs. Ahmad and Said), The overlapping characteristics of facial pain can make it MetroHealth Medical Center, Cleveland, Ohio difficult to pinpoint the cause. This article, with a handy at-a-glance table, can help. [email protected] The authors reported no potential conflict of interest relevant to this article. acial pain is a common complaint: Up to 22% of adults PracticE in the United States experience orofacial pain during recommendationS F any 6-month period.1 Yet this type of pain can be dif- › Advise patients who have a ficult to diagnose due to the many structures of the face and temporomandibular mouth, pain referral patterns, and insufficient diagnostic tools. disorder that in addition to Specifically, extraoral facial pain can be the result of tem- taking their medication as poromandibular disorders, neuropathic disorders, vascular prescribed, they should limit disorders, or atypical causes, whereas facial pain stemming activities that require moving their jaw, modify their diet, from inside the mouth can have a dental or nondental cause and minimize stress; they (FIGURE). Overlapping characteristics can make it difficult to may require physical therapy distinguish these disorders. To help you to better diagnose and and therapeutic exercises. C manage facial pain, we describe the most common causes and underlying pathological processes. › Consider prescribing a tricyclic antidepressant for patients with persistent idiopathic facial pain. C Extraoral facial pain Extraoral pain refers to the pain that occurs on the face out- 2-15 Strength of recommendation (SoR) side of the oral cavity.
    [Show full text]
  • Oral Candidiasis: a Review
    International Journal of Pharmacy and Pharmaceutical Sciences ISSN- 0975-1491 Vol 2, Issue 4, 2010 Review Article ORAL CANDIDIASIS: A REVIEW YUVRAJ SINGH DANGI1, MURARI LAL SONI1, KAMTA PRASAD NAMDEO1 Institute of Pharmaceutical Sciences, Guru Ghasidas Central University, Bilaspur (C.G.) – 49500 Email: [email protected] Received: 13 Jun 2010, Revised and Accepted: 16 July 2010 ABSTRACT Candidiasis, a common opportunistic fungal infection of the oral cavity, may be a cause of discomfort in dental patients. The article reviews common clinical types of candidiasis, its diagnosis current treatment modalities with emphasis on the role of prevention of recurrence in the susceptible dental patient. The dental hygienist can play an important role in education of patients to prevent recurrence. The frequency of invasive fungal infections (IFIs) has increased over the last decade with the rise in at‐risk populations of patients. The morbidity and mortality of IFIs are high and management of these conditions is a great challenge. With the widespread adoption of antifungal prophylaxis, the epidemiology of invasive fungal pathogens has changed. Non‐albicans Candida, non‐fumigatus Aspergillus and moulds other than Aspergillus have become increasingly recognised causes of invasive diseases. These emerging fungi are characterised by resistance or lower susceptibility to standard antifungal agents. Oral candidiasis is a common fungal infection in patients with an impaired immune system, such as those undergoing chemotherapy for cancer and patients with AIDS. It has a high morbidity amongst the latter group with approximately 85% of patients being infected at some point during the course of their illness. A major predisposing factor in HIV‐infected patients is a decreased CD4 T‐cell count.
    [Show full text]
  • Healthcare Providers* Report Immediately by Phone!
    Effective July 2008 COMMUNICABLE AND OTHER INFECTIOUS DISEASES REPORTABLE IN MASSACHUSETTS BY HEALTHCARE PROVIDERS* *The list of reportable diseases is not limited to those designated below and includes only those which are primarily reportable by clinical providers. A full list of reportable diseases in Massachusetts is detailed in 105 CMR 300.100. REPORT IMMEDIATELY BY PHONE! This includes both suspect and confirmed cases. All cases should be reported to your local board of health; if unavailable, call the Massachusetts Department of Public Health: Telephone: (617) 983-6800 Confidential Fax: (617) 983-6813 • REPORT PROMPTLY (WITHIN 1-2 BUSINESS DAYS). This includes both suspect and confirmed cases. All cases should be reported to your local board of health; if unavailable, call the Massachusetts Department of Public Health: Telephone: (617) 983-6800 Confidential Fax: (617) 983-6813 • Anaplasmosis • Leptospirosis Anthrax • Lyme disease Any case of an unusual illness thought to have Measles public health implications • Melioidosis Any cluster/outbreak of illness, including but not Meningitis, bacterial, community acquired limited to foodborne illness • Meningitis, viral (aseptic), and other infectious Botulism (non-bacterial) Brucellosis Meningococcal disease, invasive • Chagas disease (Neisseria meningitidis) • Creutzfeldt-Jakob disease (CJD) and variant CJD Monkeypox or other orthopox virus Diphtheria • Mumps • Ehrlichiosis • Pertussis • Encephalitis, any cause Plague • Food poisoning and toxicity (includes poisoning
    [Show full text]
  • WO 2014/134709 Al 12 September 2014 (12.09.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/134709 Al 12 September 2014 (12.09.2014) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/05 (2006.01) A61P 31/02 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/CA20 14/000 174 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 4 March 2014 (04.03.2014) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (26) Publication Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (30) Priority Data: ZW. 13/790,91 1 8 March 2013 (08.03.2013) US (84) Designated States (unless otherwise indicated, for every (71) Applicant: LABORATOIRE M2 [CA/CA]; 4005-A, rue kind of regional protection available): ARIPO (BW, GH, de la Garlock, Sherbrooke, Quebec J1L 1W9 (CA). GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (72) Inventors: LEMIRE, Gaetan; 6505, rue de la fougere, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Sherbrooke, Quebec JIN 3W3 (CA).
    [Show full text]
  • 2012 Case Definitions Infectious Disease
    Arizona Department of Health Services Case Definitions for Reportable Communicable Morbidities 2012 TABLE OF CONTENTS Definition of Terms Used in Case Classification .......................................................................................................... 6 Definition of Bi-national Case ............................................................................................................................................. 7 ------------------------------------------------------------------------------------------------------- ............................................... 7 AMEBIASIS ............................................................................................................................................................................. 8 ANTHRAX (β) ......................................................................................................................................................................... 9 ASEPTIC MENINGITIS (viral) ......................................................................................................................................... 11 BASIDIOBOLOMYCOSIS ................................................................................................................................................. 12 BOTULISM, FOODBORNE (β) ....................................................................................................................................... 13 BOTULISM, INFANT (β) ...................................................................................................................................................
    [Show full text]
  • Feline Alveolar Osteitis Treatment Planning: Implant Protocol with Osseodensification and Early Crown Placement Rocco E
    Feline Alveolar Osteitis Treatment Planning: Implant Protocol with Osseodensification and Early Crown Placement Rocco E. Mele DVM1, Gregori M. Kurtzman, DDS, MAGD, DICOI,DIDIA2 1 Eastpoint Pet Clinic, Tucson, A, USA 2 Silver Spring, MD, USA Abstract: Feline dental implants are becoming a predictable and viable treatment option for the replacement of lost canines due to maxillary Alveolar Osteitis (AO) a painful condition, commonly experienced by a growing number of cats. Surgical extraction and debridement remains the treatment of choice for this complex inflammatory process. However, future complications can be a common sequela of maxillary canine loss. This case will demonstrate the successful surgical extraction of a maxillary canine with implant placement following the osseodensification protocol and utilizing the sockets osteitis buttressing bone formation to promote a positive result with final crown restoration 13 weeks following implant placement. Introduction: Alveolar Osteitis (AO) is a chronic inflammatory process more often diagnosed in maxillary canine sockets of the feline patient. Clinical presentation may include oral pain, bleeding, periodontitis, tooth resorption (ORL), and alveolar buccal bone changes.1-5 Clinical Features: A presumptive diagnosis of (AO) is made on the awake patient, documenting clinical features such as; gingivitis with soft tissue swelling, gingival mucosal erythema, buccal bone expansion, and coronal extrusion. (Figure 1) Radiographic Features: Radiographic changes are identified under general anesthesia. These bony changes and pathology may include; deep palatal probing (Figure 2 red), alveolar bone expansion (Figure 2 green), buttressing condensing bone (Figure 2 blue) and a mottled osseous appearance mimicking rough, large trabeculae (Figure 2 yellow) Osseodensification (OD): OD is a novel biomechanical bone preparation technique for dental implant placement to improve bone quality by increasing its density utilizing Densah burs.
    [Show full text]
  • Medical Management of Biological Casualties Handbook
    USAMRIID’s MEDICAL MANAGEMENT OF BIOLOGICAL CASUALTIES HANDBOOK Sixth Edition April 2005 U.S. ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES FORT DETRICK FREDERICK, MARYLAND Emergency Response Numbers National Response Center: 1-800-424-8802 or (for chem/bio hazards & terrorist events) 1-202-267-2675 National Domestic Preparedness Office: 1-202-324-9025 (for civilian use) Domestic Preparedness Chem/Bio Helpline: 1-410-436-4484 or (Edgewood Ops Center – for military use) DSN 584-4484 USAMRIID’s Emergency Response Line: 1-888-872-7443 CDC'S Emergency Response Line: 1-770-488-7100 Handbook Download Site An Adobe Acrobat Reader (pdf file) version of this handbook can be downloaded from the internet at the following url: http://www.usamriid.army.mil USAMRIID’s MEDICAL MANAGEMENT OF BIOLOGICAL CASUALTIES HANDBOOK Sixth Edition April 2005 Lead Editor Lt Col Jon B. Woods, MC, USAF Contributing Editors CAPT Robert G. Darling, MC, USN LTC Zygmunt F. Dembek, MS, USAR Lt Col Bridget K. Carr, MSC, USAF COL Ted J. Cieslak, MC, USA LCDR James V. Lawler, MC, USN MAJ Anthony C. Littrell, MC, USA LTC Mark G. Kortepeter, MC, USA LTC Nelson W. Rebert, MS, USA LTC Scott A. Stanek, MC, USA COL James W. Martin, MC, USA Comments and suggestions are appreciated and should be addressed to: Operational Medicine Department Attn: MCMR-UIM-O U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) Fort Detrick, Maryland 21702-5011 PREFACE TO THE SIXTH EDITION The Medical Management of Biological Casualties Handbook, which has become affectionately known as the "Blue Book," has been enormously successful - far beyond our expectations.
    [Show full text]
  • Clinical Biotechnology and Microbiology ISSN: 2575-4750
    Page 47 to 49 Volume 1 • Issue 1 • 2017 Research Article Clinical Biotechnology and Microbiology ISSN: 2575-4750 Aspergillosis: A Highly Infectious Global Mycosis of Human and Animal Mahendra Pal* Narayan Consultancy on Veterinary Public Health and Microbiology, 4 Aangan, Ganesh Dairy Road, Anand-388001, India *Corresponding Author: Mahendra Pal, Narayan Consultancy on Veterinary Public Health and Microbiology, 4 Aangan, Ganesh Dairy Road, Anand-388001, India. Received: June 09, 2017; Published: June 19, 2017 Abstract Aspergillosis is an important opportunistic fungal saprozoonosis of worldwide distribution. The disease is reported in humans and animals including birds, and is caused primarily by Aspergillus fumigatus, a saprobic fungus of ubiquitous distribution. It occurs in aspergillosis are re- sporadic and epidemic form causing significant morbidity and mortality. Globally, over 200,000 cases of invasive ported each year. The source of infection is exogenous and respiratory tract is the chief portal of entry of fungus. A variety of clinical aspergillosis. The pathogen can signs are observed in humans and animals. Direct demonstration of fungal agent in clinical material and its isolation in pure growth be easily isolated on APRM agar. Detailed morphology of fungus is studied in Narayan stain. Numerous antifungal drugs are used in on mycological medium is still considered the gold standard to confirm an unequivocal diagnosis of clinical practice to treat cases of aspergillosis - . Certain high risk groups should use face mask to prevent inhalation of fungal spores from immediate environment. It is recommended that “APRM medium” and “Narayan stain”, which are easy to prepare and less ex including Aspergillus pensive than other stains and media, should be routinely used in microbiology and public health laboratories for the study of fungi consequences of disease.
    [Show full text]